**21:** Brod SA. Related Articles, Links

Ingested type I interferon: state of the art as treatment for autoimmunity.
Exp Biol Med (Maywood). 2002 Dec;227(11):981-8. Review.
PMID: 12486207 [PubMed - indexed for MEDLINE]

**22:** Furst DE, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Bijlsma JW, Burmester GR, Cronstein B, Keystone EC, Kavanaugh A, Klareskog L. Related Articles, Links

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).
Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii2-7. Review. No abstract available.
PMID: 12379612 [PubMed - indexed for MEDLINE]

**23:** Chikanza IC. Related Articles, Links

Mechanisms of corticosteroid resistance in rheumatoid arthritis: a putative role for the corticosteroid receptor beta isoform.
Ann N Y Acad Sci. 2002 Jun;966:39-48. Review.
PMID: 12114257 [PubMed - indexed for MEDLINE]

**24:** Waldmann T. Related Articles, Links

The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases.
Arthritis Res. 2002;4 Suppl 3:S161-7. Epub 2002 May 9. Review.
PMID: 12110135 [PubMed - indexed for MEDLINE]

**25:** LeMaistre CF. Related Articles, Links

DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential

applications.
Clin Lymphoma. 2000 Nov;1 Suppl 1:S37-40. Review.
PMID: 11707862 [PubMed - indexed for MEDLINE]

**26:** Kuzel TM. Related Articles, Links

DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date.
Clin Lymphoma. 2000 Nov;1 Suppl 1:S33-6. Review.
PMID: 11707861 [PubMed - indexed for MEDLINE]

**27:** Foss FM. Related Articles, Links

DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
Clin Lymphoma. 2000 Sep;1(2):110-6; discussion 117. Review.
PMID: 11707818 [PubMed - indexed for MEDLINE]

**28:** Foss FM. Related Articles, Links

Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Ann N Y Acad Sci. 2001 Sep;941:166-76. Review.
PMID: 11594570 [PubMed - indexed for MEDLINE]

**29:** Biesiada L, Krasomski G, Tchorzewski H. Related Articles, Links

[Current opinions on immunological processes in rheumatoid arthritis during pregnancy]
Pol Merkur Lekarski. 2001 Jun;10(60):477-9. Review. Polish.
PMID: 11503269 [PubMed - indexed for MEDLINE]

**30:** Chikanza IC, Petrou P, Chrousos G. Related Articles, Links

Perturbations of arginine vasopressin secretion during inflammatory stress. Pathophysiologic implications.
Ann N Y Acad Sci. 2000;917:825-34. Review.
PMID: 11268412 [PubMed - indexed for MEDLINE]

**31:** Maestroni GJ. Related Articles, Links

The immunotherapeutic potential of melatonin.
Expert Opin Investig Drugs. 2001 Mar;10(3):467-76. Review.
PMID: 11227046 [PubMed - indexed for MEDLINE]

**32:** Umezawa K, Ariga A, Matsumoto N. Related Articles, Links

Naturally occurring and synthetic inhibitors of NF-kappaB functions.
Anticancer Drug Des. 2000 Aug;15(4):239-44. Review.
PMID: 11200499 [PubMed - indexed for MEDLINE]

**33:** Brod SA. Related Articles, Links

Unregulated inflammation shortens human functional longevity.
Inflamm Res. 2000 Nov;49(11):561-70. Review.
PMID: 11131295 [PubMed - indexed for MEDLINE]

**34:** Ioannou Y, Isenberg DA. Related Articles, Links

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.
Arthritis Rheum. 2000 Jul;43(7):1431-42. Review. No abstract available.
PMID: 10902743 [PubMed - indexed for MEDLINE]

**35:** Panayi GS. Related Articles, Links

Targeting of cells involved in the pathogenesis of rheumatoid arthritis.
Rheumatology (Oxford). 1999 Nov;38 Suppl 2:8-10. Review.
PMID: 10646482 [PubMed - indexed for MEDLINE]

**36:** Antonen J, Saha H, Hulkkonen J, Lumio J, Pasternack A, Hurme M. Related Articles, Links

Increased in vitro production of interleukin 6 in response to trimethoprim among persons with trimethoprim induced systemic adverse reactions.
J Rheumatol. 1999 Dec;26(12):2585-90. Review.
PMID: 10606366 [PubMed - indexed for MEDLINE]

**37:** Chikanza IC. Related Articles, Links

Prolactin and neuroimmunomodulation: in vitro and in vivo observations.
Ann N Y Acad Sci. 1999 Jun 22;876:119-30. Review.
PMID: 10415600 [PubMed - indexed for MEDLINE]

**38:** Dinant HJ, Dijkmans BA. Related Articles, Links

New therapeutic targets for rheumatoid arthritis.
Pharm World Sci. 1999 Apr;21(2):49-59. Review.
PMID: 10380231 [PubMed - indexed for MEDLINE]

**39:** Waldmann TA, Tagaya Y. Related Articles, Links

The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens.
Annu Rev Immunol. 1999;17:19-49. Review.
PMID: 10358752 [PubMed - indexed for MEDLINE]

**40:** Breedveld F. Related Articles, Links

New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis.

Eur Cytokine Netw. 1998 Sep;9(3):233-8. Review.
PMID: 9831171 [PubMed - indexed for MEDLINE]

Items 21 - 40 of 95 Previous Page 2 of 5 Next
Display Summary Show 20 Sort by Send to



Mar 19 2007 07:18:03

About Entrez
Text Version
Entrez PubMed Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI
Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

All: 95 Review: 95

Items 21 - 40 of 95 Previous Page 2 of 5 Next

**21:** Brod SA. Related Articles, Links

Ingested type I interferon: state of the art as treatment for autoimmunity.
Exp Biol Med (Maywood). 2002 Dec;227(11):981-8. Review.
PMID: 12486207 [PubMed - indexed for MEDLINE]

**22:** Furst DE, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Bijlsma JW, Burmester GR, Cronstein B, Keystone EC, Kavanaugh A, Klareskog L. Related Articles, Links

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).
Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii2-7. Review. No abstract available.
PMID: 12379612 [PubMed - indexed for MEDLINE]

**23:** Chikanza IC. Related Articles, Links

Mechanisms of corticosteroid resistance in rheumatoid arthritis: a putative role for the corticosteroid receptor beta isoform.
Ann N Y Acad Sci. 2002 Jun;966:39-48. Review.
PMID: 12114257 [PubMed - indexed for MEDLINE]

**24:** Waldmann T. Related Articles, Links

The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases.
Arthritis Res. 2002;4 Suppl 3:S161-7. Epub 2002 May 9. Review.
PMID: 12110135 [PubMed - indexed for MEDLINE]

**25:** LeMaistre CF. Related Articles, Links

DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential

applications.
Clin Lymphoma. 2000 Nov;1 Suppl 1:S37-40. Review.
PMID: 11707862 [PubMed - indexed for MEDLINE]

**26:** Kuzel TM. Related Articles, Links

DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date.
Clin Lymphoma. 2000 Nov;1 Suppl 1:S33-6. Review.
PMID: 11707861 [PubMed - indexed for MEDLINE]

**27:** Foss FM. Related Articles, Links

DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
Clin Lymphoma. 2000 Sep;1(2):110-6; discussion 117. Review.
PMID: 11707818 [PubMed - indexed for MEDLINE]

**28:** Foss FM. Related Articles, Links

Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Ann N Y Acad Sci. 2001 Sep;941:166-76. Review.
PMID: 11594570 [PubMed - indexed for MEDLINE]

**29:** Biesiada L, Krasomski G, Tchorzewski H. Related Articles, Links

[Current opinions on immunological processes in rheumatoid arthritis during pregnancy]
Pol Merkur Lekarski. 2001 Jun;10(60):477-9. Review. Polish.
PMID: 11503269 [PubMed - indexed for MEDLINE]

**30:** Chikanza IC, Petrou P, Chrousos G. Related Articles, Links

Perturbations of arginine vasopressin secretion during inflammatory stress. Pathophysiologic implications.
Ann N Y Acad Sci. 2000;917:825-34. Review.
PMID: 11268412 [PubMed - indexed for MEDLINE]

**31:** Maestroni GJ. Related Articles, Links

The immunotherapeutic potential of melatonin.
Expert Opin Investig Drugs. 2001 Mar;10(3):467-76. Review.
PMID: 11227046 [PubMed - indexed for MEDLINE]

**32:** Umezawa K, Ariga A, Matsumoto N. Related Articles, Links

Naturally occurring and synthetic inhibitors of NF-kappaB functions.
Anticancer Drug Des. 2000 Aug;15(4):239-44. Review.
PMID: 11200499 [PubMed - indexed for MEDLINE]

**33:** Brod SA. Related Articles, Links

Unregulated inflammation shortens human functional longevity.
Inflamm Res. 2000 Nov;49(11):561-70. Review.
PMID: 11131295 [PubMed - indexed for MEDLINE]

**34:** Ioannou Y, Isenberg DA. Related Articles, Links

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.
Arthritis Rheum. 2000 Jul;43(7):1431-42. Review. No abstract available.
PMID: 10902743 [PubMed - indexed for MEDLINE]

**35:** Panayi GS. Related Articles, Links

Targeting of cells involved in the pathogenesis of rheumatoid arthritis.
Rheumatology (Oxford). 1999 Nov;38 Suppl 2:8-10. Review.
PMID: 10646482 [PubMed - indexed for MEDLINE]

**36:** Antonen J, Saha H, Hulkkonen J, Lumio J, Pasternack A, Hurme M. Related Articles, Links

Increased in vitro production of interleukin 6 in response to trimethoprim among persons with trimethoprim induced systemic adverse reactions.
J Rheumatol. 1999 Dec;26(12):2585-90. Review.
PMID: 10606366 [PubMed - indexed for MEDLINE]

**37:** Chikanza IC. Related Articles, Links

Prolactin and neuroimmunomodulation: in vitro and in vivo observations.
Ann N Y Acad Sci. 1999 Jun 22;876:119-30. Review.
PMID: 10415600 [PubMed - indexed for MEDLINE]

**38:** Dinant HJ, Dijkmans BA. Related Articles, Links

New therapeutic targets for rheumatoid arthritis.
Pharm World Sci. 1999 Apr;21(2):49-59. Review.
PMID: 10380231 [PubMed - indexed for MEDLINE]

**39:** Waldmann TA, Tagaya Y. Related Articles, Links

The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens.
Annu Rev Immunol. 1999;17:19-49. Review.
PMID: 10358752 [PubMed - indexed for MEDLINE]

**40:** Breedveld F. Related Articles, Links

New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis.

Eur Cytokine Netw. 1998 Sep;9(3):233-8. Review.
PMID: 9831171 [PubMed - indexed for MEDLINE]

Items 21 - 40 of 95 Previous Page 2 of 5 Next

Display Summary Show 20 Sort by Send to

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Mar 19 2007 07:18:03

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTASXS1656

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * *
* *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  DEC 18   CA/CAplus pre-1967 chemical substance index entries
enhanced
                   with preparation role
 NEWS  4  DEC 18   CA/CAplus patent kind codes updated
 NEWS  5  DEC 18   MARPAT to CA/CAplus accession number crossover
limit increased
                   to 50,000
 NEWS  6  DEC 18   MEDLINE updated in preparation for 2007 reload
 NEWS  7  DEC 27   CA/CAplus enhanced with more pre-1907 records
 NEWS  8  JAN 08   CHEMLIST enhanced with New Zealand Inventory of
Chemicals
 NEWS  9  JAN 16   CA/CAplus Company Name Thesaurus enhanced and
reloaded
 NEWS 10  JAN 16   IPC version 2007.01 thesaurus available on STN
 NEWS 11  JAN 16   WPIDS/WPINDEX/WPIX enhanced with IPC 8
reclassification data
 NEWS 12  JAN 22   CA/CAplus updated with revised CAS roles
 NEWS 13  JAN 22   CA/CAplus enhanced with patent applications from
India
 NEWS 14  JAN 29   PHAR reloaded with new search and display fields
 NEWS 15  JAN 29   CAS Registry Number crossover limit increased to
300,000 in
                   multiple databases
 NEWS 16  FEB 15   PATDPASPC enhanced with Drug Approval numbers
 NEWS 17  FEB 15   RUSSIAPAT enhanced with pre-1994 records
 NEWS 18  FEB 23   KOREAPAT enhanced with IPC 8 features and
functionality
 NEWS 19  FEB 26   MEDLINE reloaded with enhancements
 NEWS 20  FEB 26   EMBASE enhanced with Clinical Trial Number field
 NEWS 21  FEB 26   TOXCENTER enhanced with reloaded MEDLINE
 NEWS 22  FEB 26   IFICDB/IFIPAT/IFIUDB reloaded with enhancements
 NEWS 23  FEB 26   CAS Registry Number crossover limit increased from
10,000
```

to 300,000 in multiple databases
NEWS 24 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25 MAR 16 CASREACT coverage extended
NEWS 26 MAR 20 MARPAT now updated daily
NEWS 27 MAR 22 LWPI reloaded

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:39:26 ON 27 MAR 2007

=> File Medline EMBASE Biosis Caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'MEDLINE' ENTERED AT 16:39:45 ON 27 MAR 2007

FILE 'EMBASE' ENTERED AT 16:39:45 ON 27 MAR 2007


FILE 'BIOSIS' ENTERED AT 16:39:45 ON 27 MAR 2007


FILE 'CAPLUS' ENTERED AT 16:39:45 ON 27 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


=> s (NIK or MAP3K) near4 (624 or 947 or 640 or 720)
MISSING OPERATOR MAP3K) NEAR4

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s (NIK or MAP3K) (4A) (624 or 947 or 640 or 720)
L1 8 (NIK OR MAP3K) (4A) (624 OR 947 OR 640 OR 720)

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l1
DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS, CAPLUS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L1
L2 2 DUPLICATE REMOVE L1 (6 DUPLICATES REMOVED)

=> d l2 1-2 bib ab

L2 ANSWER 1 OF 2 MEDLINE on STN DUPLICATE 1
AN 2006187607 MEDLINE
DN PubMed ID: 16585559
TI NF-kappaB-inducing kinase is involved in the activation of the
CD28
responsive element through phosphorylation of c-Rel and
regulation of its
transactivating activity.
AU Sanchez-Valdepenas Carmen; Martin Angel G; Ramakrishnan
Parameswaran;
Wallach David; Fresno Manuel
CS Centro de Biologia Molecular, Consejo Superior de Investigaciones
Cientificas, Universidad Autonoma de Madrid, Madrid, Spain.
SO Journal of immunology (Baltimore, Md. : 1950), (2006 Apr 15)
Vol. 176, No.
8, pp. 4666-74.
Journal code: 2985117R. ISSN: 0022-1767.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200605
ED Entered STN: 5 Apr 2006
Last Updated on STN: 17 May 2006
Entered Medline: 16 May 2006
AB Previous evidence suggested that NF-kappaB-inducing kinase (NIK)
might
regulate IL-2 synthesis. However, the molecular mechanism is not
understood. In this study, we show that NIK is involved in CD3
plus CD28
activation of IL-2 transcription. Splenic T cells from aly/aly
mice (that
have a defective NIK protein) have a severe impairment in IL-2
and GM-CSF

but not TNF secretion in response to CD3/CD28. This effect takes place at the transcriptional level as overexpression of alyNIK inhibits IL-2 promoter transcription. NIK activates the CD28 responsive element (CD28RE) of the IL-2 promoter and strongly synergizes with c-Rel in this activity. We found that NIK interacts with the N-terminal domain of c-Rel, mapping this interaction to aa 771-947 of NIK. Moreover, NIK phosphorylates the c-Rel C-terminal transactivation domain (TAD) and induces Gal4-c-Rel-transactivating activity. Anti-CD28 activated Gal4-c-Rel transactivation activity, and this effect was inhibited by a NIK-defective mutant. Deletion studies mapped the region of c-Rel responsive to NIK in aa 456-540. Mutation of several serines, including Ser471, in the TAD of c-Rel abrogated the NIK-enhancing activity of its transactivating activity. Interestingly, a Jurkat mutant cell line that expresses one of the mutations of c-Rel (Ser471Asn) has a severe defect in IL-2 and CD28RE-dependent transcription in response to CD3/CD28 or to NIK. Our results support that NIK may be controlling CD28RE-dependent transcription and T cell activation by modulating c-Rel phosphorylation of the TAD. This leads to more efficient transactivation of genes which are dependent on CD28RE sites where c-Rel binds such as the IL-2 promoter.

L2 ANSWER 2 OF 2 MEDLINE on STN DUPLICATE 2
AN 2001370772 MEDLINE
DN PubMed ID: 11278268
TI Effects of the NIK aly mutation on NF-kappaB activation by the Epstein-Barr virus latent infection membrane protein, lymphotoxin beta receptor, and CD40.
AU Luftig M A; Cahir-McFarland E; Mosialos G; Kieff E
CS Departments of Microbiology and Molecular Genetics and Medicine, Program in Virology, Harvard Medical School, Boston, Massachusetts 02115, USA.
NC CA47006 (NCI)
SO The Journal of biological chemistry, (2001 May 4) Vol. 276, No. 18, pp.

14602-6. Electronic Publication: 2001-03-14.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LA English
FS Priority Journals
EM 200106
ED Entered STN: 2 Jul 2001
Last Updated on STN: 5 Jan 2003
Entered Medline: 28 Jun 2001
AB Homozygosity for the aly point mutation in NF-kappaB-inducing kinase (NIK)
results in alymphoplasia in mice, a phenotype similar to that of homozygosity for deletion of the lymphotoxin beta receptor (LTbetaR). We
now find that NF-kappaB activation by Epstein-Barr virus latent membrane
protein 1 (LMP1) or by an LMP1 transmembrane domain chimera with the
LTbetaR signaling domain in human embryonic kidney 293 cells is selectively inhibited by a wild type dominant negative NIK comprised of amino acids 624-947 (DN-NIK)
and not by aly DN-NIK. In contrast, LMP1/CD40 is inhibited by both wild
type (wt) and aly DN-NIK. LMP1, an LMP1 transmembrane domain chimera with
the LTbetaR signaling domain, and LMP1/CD40 activate NF-kappaB in wt or
aly murine embryo fibroblasts. Although wt and aly NIK do not differ in
their in vitro binding to tumor necrosis factor receptor-associated factor
1, 2, 3, or 6 or in their in vivo association with tumor necrosis factor
receptor-associated factor 2 and differ marginally in their very poor
binding to IkappaB kinase beta (IKKbeta), only wt NIK is able to bind to
IKKalpha. These data are compatible with a model in which activation of
NF-kappaB by LMP1 and LTbetaR is mediated by an interaction of NIK or a
NIK-like kinase with IKKalpha that is abrogated by the aly mutation. On
the other hand, CD40 mediates NF-kappaB activation through a kinase that
interacts with a different component of the IKK complex.